Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M(TM) adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
在南非,一项随机交叉2a/2b期试验评估了SARS-CoV-2重组刺突蛋白疫苗(含Matrix-M™佐剂,NVX-CoV2373)加强剂与基础免疫接种相比,在HIV-1感染者和未感染者中的免疫原性和安全性。
期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2024.2425147
Shinde, Vivek; Lombard Koen, Anthonet; Hoosain, Zaheer; Archary, Moherndran; Bhorat, Qasim; Fairlie, Lee; Lalloo, Umesh; Masilela, Mduduzi S L; Moodley, Dhayendre; Hanley, Sherika; Fouche, Leon Frederik; Louw, Cheryl; Tameris, Michele; Singh, Nishanta; Goga, Ameena; Dheda, Keertan; Grobbelaar, Coert; Joseph, Natasha; Lombaard, Johan J; Mngqibisa, Rosie; Bhorat, As'ad Ebrahim; Benadé, Gabriella; Lalloo, Natasha; Pitsi, Anna; Vollgraaff, Pieter-Louis; Luabeya, Angelique; Esmail, Aliasgar; Petrick, Friedrich G; Oommen Jose, Aylin; Foulkes, Sharne; Ahmed, Khatija; Thombrayil, Asha; Kalonji, Dishiki; Cloney-Clark, Shane; Zhu, Mingzhu; Bennett, Chijioke; Albert, Gary; Marcheschi, Alex; Plested, Joyce S; Neal, Susan; Chau, Gordon; Cho, Iksung; Fries, Louis; Glenn, Greg M; Madhi, Shabir A
SARS-CoV-2
HIV
炎症/感染
微生物学
免疫/内分泌